Aldometanib

Description: Aldometanib (LXY-05-029) is an orally active aldolase inhibitor that prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK, useful in metabolic homeostasis research [1]. Target: Others, AMPK. Smiles: CC1=[N+](C=CN1CCCCCCCCCC CCCCCC)CC2=C(Cl)C=CC=C2Cl.[I-]. References: Zhang CS, et al. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat Metab. 2022 Oct,4(10):1369-1401.